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Apolipoprotein H (ApoH) is a multi-functional plasma glycoprotein that has been associated with 
negative health outcomes. ApoH levels have high heritability. We undertook a genome-wide association 
study of ApoH levels using the largest sample to date and replicated the results in an independent 
cohort (total N = 1,255). In the discovery phase, a meta-analysis of two cohorts, the Sydney Memory 
and Ageing Study (Sydney MAS) and the Older Australian Twins Study (OATS) (n = 942) revealed 
genome-wide significant results in or near the APOH gene on chromosome 17 (top SNP, rs7211380, 
p = 1 × 10−11). The results were replicated in an independent cohort, the Hunter Community 
Study (p < 0.002) (n = 313). Conditional and joint analysis (COJO) confirmed the association of the 
chromosomal 17 region with ApoH levels. The set of independent SNPs identified by COJO explained 
23% of the variance. The relationships between the top SNPs and cardiovascular/lipid/cognition 
measures and diabetes were assessed in Sydney MAS, with suggestive results observed for diabetes 
and cognitive performance. However, replication of these results in the smaller OATS cohort was not 
found. This work provides impetus for future research to better understand the contribution of genetics 
to ApoH levels and its possible impacts on health.
Apolipoproteins are a family of multifunctional glycoproteins that bind and transport lipids in the circulatory 
system. Apolipoprotein H (ApoH), also known as β 2-glycoprotein I (β 2GPI), is a 43–50 kDa single-chain gly-
coprotein that is expressed predominantly in the liver but also in other cell types such as endothelial cells, lym-
phocytes, astrocytes and neurons1,2. ApoH is a phospholipid-binding (e.g. cardiolipin) plasma protein that also 
binds other negatively charged molecules such as DNA and oxidised low-density lipoproteins and interacts 
with a variety of proteins3,4. It is involved in a number of physiological processes including lipid metabolism, 
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coagulation, apoptosis, host defence against bacterial infections, inflammation, angiogenesis and atherogene-
sis3,5–7. Importantly, ApoH is the main target of anti-phospholipid antibodies (aPLs) found in many patients with 
systemic lupus erythematosus and antiphospholipid syndrome (APS)3,7–9. APS is characterised by thrombosis and 
pregnancy complications including miscarriage. aPLs, which include those directed against ApoH, are also found 
in a small proportion of the general population and become more common with ageing10–12. ApoH levels have 
also been linked to cognitive ageing, the predementia syndrome, mild cognitive impairment, and Alzheimer’s 
disease13–17. Thus ApoH is potentially involved in a wide range of health outcomes and a better understanding of 
the factors influencing its levels is required to elucidate the roles ApoH may play in disease.
Genetics plays a strong role in determining ApoH levels as demonstrated by the high heritability (78%) of 
plasma ApoH levels18. The APOH gene is located on chromosome 17 and has 8 exons19,20. Previous studies have 
demonstrated that variation in the APOH gene influences plasma ApoH levels. Two missense APOH single nucle-
otide polymorphisms (SNPs) (rs1801692 [Ser107Asn, also known as Ser88Asn], rs1801690 [Trp335Ser, also 
known as Trp316Ser]) explained up to 14% of the observed plasma ApoH variation in Caucasians with a mean 
age of ~53 years7,21. Rs1801690 and another missense SNP, rs1801689 [Cys325Gly, also known as Cys306Gly], 
were also associated with ApoH levels in lupus patients22. Furthermore, rs1801690 and three other APOH SNPs 
in high linkage disequilibrium (LD) were associated with increased risk of venous thrombosis and ApoH lev-
els in a Chinese sample23. In a later study, Mehdi et al.24 observed reduced gene expression and lower plasma 
ApoH levels for the minor allele of an APOH polymorphism located next to the transcriptional initiation site 
(-1C- > A), rs8178822, which may interfere with the binding of the transcription factor, TFIID24. In addition, 
Suresh et al.25 have described several APOH promoter SNPs that influence transcription in vitro, including 
rs8178822, rs3760292 (− 643 from translation start) and rs8178819 (−1219 from translation start). However, 
when the relationships between these SNPs were investigated with ApoH levels in human blood; only rs8178822 
was significant, which may reflect the differences between in vitro experiments and the more complex in vivo 
human samples.
One previous genome-wide association study (GWAS) has been reported but used a small family sample 
(N = 306) and did not have a healthy replication sample7. The authors examined the associations of plasma 
ApoH levels with over 300,000 SNPs. Three SNPs reached genome-wide significance (p ≤ 1.76 × 10−7), which 
were located in the ELF5 and SCUBE2 genes. Suggestive evidence was observed for several SNPs, including a 
variant located in the APOH gene and several SNPs located nearby. The three genome-wide significant results 
were then investigated further by examining their association with coronary artery disease (CAD) using a large 
sample (n = 5,765 CAD; n = 7,624 controls) with two linked SNPs, located in the ELF5 gene region, nominally 
significant.
In this study, we aimed to identify novel genetic variants associated with ApoH levels by undertaking a larger 
GWAS in a sample of middle-aged to older adults. The discovery phase was undertaken in two Australian cohorts 
of older adults (n = 942). Genome-wide significant results for ApoH levels were observed in or near the APOH 
gene on chromosome 17. These results were replicated in an independent study of middle-aged to older adults 
(n = 313). Furthermore, the relationship between the identified SNPs and cardiovascular-related phenotypes, 
diabetes and cognitive performance was also assessed.
Results
Descriptive statistics for the three cohorts are shown in Table 1. Of the three cohorts, the Sydney Memory and 
Ageing Study (Sydney MAS) cohort was the oldest and the Hunter Community Study (HCS) the youngest, as it 
included individuals aged 55 years and over. Current use of hypolipidemic medication was common in the two 
older cohorts (Sydney MAS, Older Australian Twin Study [OATS]).
Genome-wide Association Analyses (GWAS). GWAS were undertaken using linear regression models 
in each of the cohorts. In the discovery phase using a meta-analysis of the GWAS results from the two cohorts, 
Sydney MAS and OATS, twelve genome-wide significant SNPs were observed (p < 5 × 10−8) when age, sex and 
hypolipidemic medication were used as covariates (Model 2, Fig. 1, Table 2). The results for Model 1 (only age, sex 
and batch number as covariates) are shown in Supplementary Tables S1 and S2, with most of the results overlap-
ping between the two models. All of the genome-wide SNPs were located in or close to the APOH gene region and 
in general were in high linkage disequilibrium (Table 2, Fig. 2). Replication of the genome-wide significant results 
was undertaken in HCS and all SNPs showed evidence of replication (p < 0.002, Table 2), even after Bonferroni 
correction (p = 0.05/12 tests = 0.004).
Sydney MAS OATS HCS
Sample size 603 339 313
Age (yrs), M (SD) 78.22 (4.54) 70.58 (5.24) 66.28 (8.06)
Number females (%) 337 (55.9) 202 (59.6) 144 (46.0)
Plasma ApoH Levels (ug/ml), median (IQR) 164.9 (IQR = 135.6–190.0) 136.87 (IQR = 94.76–170.0) 146.73 (IQR = 110.1–180.3)
Current hypolipidemic medication use N, (%) 288 (47.8) 123 (36.3) 97 (31.0)
Genotyping platform Affymetrix 6.0 Illumina OmniExpress Affymetrix Axiom Kaiser array
Table 1.  Descriptive statistics for the discovery cohorts (Sydney Memory and Ageing Study, Older 
Australian Twins Study) and the replication cohort (Hunter Community Study). Sydney MAS = Sydney 
Memory and Ageing Study, OATS = Older Australian Twins Study, HCS = Hunter Community Study.
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The most significant SNP (rs7211380) was located 3′ to the APOH gene and explained 3.7% of the variance 
(see Table 2). The other APOH SNPs were spread across the gene including a non-synonymous SNP, which results 
in the substitution of arginine with histidine at amino acid 154 (rs817884, also known as Arg135His). As shown 
in Table 3, several suggestive SNPs in the CEP112 gene (p < 1 × 10−5) also showed evidence of replication in the 
HCS (p ≤ 0.02), but did not survive Bonferroni correction for multiple testing (p = 0.05/13 tests = 0.004). The 
GWAS discovery summary results are available at https://www.cheba.unsw.edu.au/group/genetics-genomics.
Conditional and Joint Analyses. To investigate further a conditional and joint analysis (COJO) was 
undertaken using the meta-analysis results for Sydney MAS and OATS, when adjusted for age, sex, assay batch 
number and hypolipidemic medication. In the final model (see Supplementary Table S3), only chromosomal 17 
SNPs were identified, including SNPs not identified in the meta-analysis (cf Tables 2 and 3). These SNPs were 
spread over a 10,227,682 bp region containing the APOH, CEP112 and PRKCA genes and explained 23% of the 
variance in ApoH levels.
Replication of prior genetic results. Prior Genetic Studies. Six SNPs located in or near the APOH gene 
have been previously associated with ApoH levels using in vitro experiments and/or human samples. These SNPs 
are rs1801692 (exon 3, Ser107Asn), rs1801690 (exon 8, Trp335Ser)21, rs3760292 (− 632 from transcription start 
site), rs8178819 (− 1219 from transcription start site), the missense SNP rs4791077 now known as rs1801689 
(Cys325Gly) and rs8178822 (5′ UTR, − 32 from translational start site)24.
Rs8178822, was identified as a genome-wide significant hit in our GWAS. Rs3760292 was available in all 
three cohorts but was not significantly associated with ApoH levels (p > 0.311). The other four SNPs (rs1801690, 
rs1801692, rs8178819, rs1801689) were only available in OATS and HCS. Rs1801690, was significant in both 
OATS (p = 5.53 × 10−6) and HCS (p = 0.0001) as was rs1801689 (OATS, p = 0.002; HCS p = 2.46 × 10−5) and the 
results were in the same direction in both cohorts. The SNP rs8178819 approached nominal significance (OATS 
p = 0.075, HCS p = 0.053) but rs1801692 was not significant (p > 0.17).
Prior GWAS. Of the ten SNPs identified in the previously published GWAS (see Supplementary Table S4)7, 
only three SNPs showed suggestive evidence of replication in the Sydney MAS/OATS meta-analysis (rs2647528 
p = 0.008, rs7209395 p = 0.037, rs10048158 [APOH], p = 0.016) but none survived Bonferroni correction for 
multiple testing.
Investigation of top SNPs with cardiovascular phenotypes, diabetes and cognition. The asso-
ciations of the top 25 SNPs identified in the GWAS (genome-wide significant plus suggestive) with cardiovascular 
phenotypes (myocardial infarction, stroke, hypertension, HDL and LDL cholesterol levels), diabetes and cog-
nitive performance were examined. In Sydney MAS, two SNPs were nominally associated with type 2 diabetes 
(rs2010251, rs758767), with an odds ratio of 1.67 (p = 0.015) (see Table 4). The SNP rs2873966 was associated 
with the cognitive domains of attention/processing speed (p = 0.001), executive function (p = 0.014) and global 
cognition (p = 0.001). Two other SNPs also showed evidence of association with attention/processing speed 
(rs2010251, rs758767). Replication of these results was undertaken in OATS with one SNP approaching nominal 
significance (rs287396) for the cognitive domain of attention/processing speed (p = 0.054) and showing nominal 
Figure 1. Manhattan Plot: Results of the Discovery Plasma ApoH GWAS (Model 2 = age, sex, assay batch, 
hypolipidemic medication). P-values for each individual SNP are plotted against chromosome position from 
the results of the discovery association analyses for plasma ApoH levels.
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significance for global cognition (p = 0.047). However, these results were in the opposite direction and were not 
significant after adjusting for multiple testing.
Discussion
In our study we investigated the genetics of plasma apolipoprotein H levels in community-dwelling cohorts of 
older adults using a GWAS meta-analysis. Our results were replicated in an independent cohort of middle-aged 
to older adults. Consistent with prior results we observed SNPs in and around the APOH gene on chromosome 17 
that contributed to the variance observed in plasma ApoH levels. Furthermore, when we undertook a conditional 
and joint analysis, only a region on chromosome 17 was significantly associated with ApoH levels. The joint anal-
ysis identified new SNPs that were not GWAS-significant in the single SNP analysis. These SNPs explained 23% 
of the variance in ApoH levels. We extended these analyses to examine whether these SNPs were associated with 
diabetes, cardiovascular and cognitive phenotypes. Indeed, several APOH SNPs were nominally associated with 
diabetes and cognitive performance in the Sydney MAS but not in the smaller OATS cohort. We also replicated 
prior candidate gene results for the missense variants, rs1801690 and rs1801689.











rs7211380 17 64206768 G − 1.20 (0.19) 8.15E-11 − − 0.037 0.000517 − APOH 3′ 
rs11651658 17 64198640 C − 1.19 (0.18) 1.02E-10 − − 0.036 0.000872 − NA Near APOH
rs1014399 17 64196331 A − 1.16 (0.18) 2.20E-10 − − 0.035 0.001453 − NA Near APOH
rs8178853 17 64215058 A − 1.12 (0.19) 3.82E-09 − − 0.030 0.001138 − APOH intron
rs8178851 17 64215239 C − 1.12 (0.19) 3.85E-09 − − 0.030 0.001141 − APOH intron
rs8178841 17 64219197 A − 1.12 (0.19) 3.86E-09 − − 0.030 0.001157 − APOH intron
rs8178838 17 64219541 C − 1.12 (0.19) 3.92E-09 − − 0.030 0.001139 − APOH intron
rs16958979 17 64223859 T − 1.12 (0.19) 4.01E-09 − − 0.030 0.001116 − APOH intron
rs7213041 17 64224616 T − 1.12 (0.19) 4.01E-09 − − 0.030 0.001112 − APOH intron
rs8178847 17 64216815 T − 1.12 (0.19) 4.26E-09 − − 0.030 0.001157 − APOH missense (Arg –> His)
rs8178822 17 64225529 T − 1.12 (0.19) 4.27E-09 − − 0.030 0.001122 − APOH UTR 5′ 
rs8178842 17 64218640 T − 1.12 (0.19) 4.29E-09 − − 0.030 0.001157 − APOH Intron
Table 2.  Genome-wide significant plasma ApoH GWAS results for the discovery meta-analysis and the 
replication sample for Model 2 (age, sex, assay batch, hypolipidemic medication). Note: SNP annotation 
information from SNPnexus43; Genomic inflation factor (λ GC) for the discovery sample was 0.995; Variance 
explained = 2*p*q*beta2/Variance of ApoH, allele frequencies were estimated using Sydney MAS and ApoH 
variance from the discovery analysis; APOH = apolipoprotein H.
Figure 2. Linkage disequilibrium plot for the top ApoH genome-wide significant SNP (rs7211380) and 
surrounding SNPs in a 200 base pair window based on the 1K Genomes reference panel using CEU samples. 
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Most of the identified APOH GWAS SNPs are in linkage disequilibrium. Interestingly, our top SNP, rs7211380, 
was not in linkage disequilibrium with the suggestive APOH SNP observed by Athaniasadis et al.7 (rs10048158, 
r2 = 0.046). This SNP (rs7211380) is located 3′ to the APOH gene. However, previous work provides clues to the 
SNPs that may be driving the observed relationships in this study. For example, the minor allele of the 5′ UTR 
genome-wide significant SNP, rs8178822, located next to the transcription start site, has been previously linked to 
lower gene and protein expression in vitro and in vivo24,25. Moreover, our results were in a similar direction to that 
previously observed24. Our top SNP rs7211380 is in high LD with rs8178822 (r2 = 0.90). Another top GWAS SNP 
of interest is the non-synonymous coding SNP, rs8178847, which results in the substitution of arginine with histi-
dine, which may have implications for the integrity of the protein. However, analysis using SIFT26, suggested this 
amino acid substitution would not be deleterious to protein function. This SNP has previously been associated 
with body mass index in type 2 diabetic patients receiving thiazolidinedione therapy27. Using a gene-based anal-
ysis VEGAS28, only the APOH locus was significant (p = 1 × 10−7, data not shown). In addition, pathway analysis 
of our top GWAS results using software packages such as MAGENTA29 and iGSEA4GWAS30 did not reveal any 
significantly enriched pathways (results not shown) as most of our top results were observed in and around the 
APOH gene on chromosome 17.
By undertaking a conditional and joint analysis we were able to identify independent SNPs on chromosome 
17 that were not genome-wide significant in the single SNP meta-analysis. For example, the CEP112 intronic 
SNP rs9897921 had a p-value of 0.00012 in the single SNP analysis but in the joint analysis had a p-value of 
2.8 × 10−220. This analysis implicated a wide region of chromosome 17 (10,226 kb). However, the majority of 
SNPs were located in a region of 617 kb encompassing not only APOH but also the CEP112 and PRKCA genes. 
The remaining two SNPs were located in an intergenic region and were not in LD with our top SNP, rs7211380 
(r2 = 0). Overall, the identified SNPs in this analysis explained a relatively large proportion of the phenotypic 
variance (23%).
None of the ten SNPs identified from the previous GWAS7 were significant in our discovery meta-analysis. 
However, three SNPs showed suggestive evidence of replication in our larger sample, one of which was located 











rs2873966 17 64211973 A 0.53 (0.10) 2.54E-07 + + 0.025 0.068927 + APOH intronic
rs11655503 17 64027346 A − 0.97 (0.19) 4.24E-07 − − 0.028 0.010205 − CEP112 intronic
rs8064837 17 64242703 G − 0.46 (0.09) 5.11E-07 − − 0.023 0.113782 − N/A N/A
rs1420791 17 63914750 G − 0.92 (0.19) 8.90E-07 − − 0.022 0.011073 − CEP112 intronic
rs2010251 17 64203725 T − 0.61 (0.13) 1.26E-06 − − 0.022 0.03413 − N/A N/A
rs758767 17 64204591 A − 0.61 (0.13) 1.26E-06 − − 0.022 0.034137 − N/A N/A
rs7214750 17 63903119 T − 0.90 (0.19) 1.30E-06 − − 0.021 0.015964 − CEP112 intronic
rs6431248 2 235202974 A 0.46 (0.10) 3.00E-06 + + 0.021 0.722578 + N/A N/A
rs181247 17 56207731 A 0.58 (0.13) 4.88E-06 + + 0.028 0.021183 + N/A N/A
rs12825437 12 5756980 A − 0.65 (0.14) 5.91E-06 − − 0.019 0.486807 + TMEM16B intronic
rs1519187 2 235201218 T 0.45 (0.10) 7.18E-06 + + 0.02 0.876655 + N/A N/A
rs9562709 13 47727650 A 0.48 (0.11) 8.83E-06 + + 0.018 0.488741 − N/A N/A
rs9591011 13 47728087 T 0.48 (0.11) 9.04E-06 + + 0.017 0.488816 − N/A N/A
Table 3.  Suggestive plasma ApoH GWAS results for the discovery meta-analysis and the replication sample 
for Model 2 (age, sex, assay batch effects, hypolipidemic medication). Note: SNP annotation information 
from SNPnexus43; Variance explained = 2*p*q*beta2/Variance of ApoH, allele frequencies were estimated using 
Sydney MAS and ApoH variance from the discovery analysis; APOH, apolipoprotein H; CEP112, centrosomal 










Diabetes Type 2 rs2010251 T − 1.668 (0.210) 0.015 925 T 0.010 (0.029) 0.730 512
Diabetes Type 2 rs758767 A − 1.668 (0.210) 0.015 925 A 0.010 (0.029) 0.730 512
Attention/Processing Speed rs2010251 T − 0.163 (0.073) 0.026 909 T 0.072 (0.077) 0.350 503
Attention/Processing Speed rs758767 A − 0.163 (0.073) 0.026 909 A 0.072 (0.077 0.350 503
Attention/Processing Speed rs2873966 A 0.194 (0.056) 0.001 909 A − 0.141 (0.073) 0.054 503
Executive function rs2873966 A 0.149 (0.061) 0.014 851 A − 0.081 (0.076) 0.280 499
Global cognition rs2873966 A 0.189 (0.057) 0.001 921 A − 0.14 (0.070) 0.047 505
Table 4.  SNPs nominally to significantly associated with diabetes type 2 and cognitive domains in the 
Sydney Memory and Ageing Study (MAS) and replication results from the Older Australian Twins Study 
(OATS). S.E. = standard error for odds ratio (OR) or beta value.
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close to the APOH gene (rs10048158). Methodological differences between the two studies may contribute to 
the lack of replication of the prior GWAS results including the larger sample size of the present study (N = 942 
discovery versus N = 306) and the different immunoassay methods used for measurement of ApoH levels. Our 
sample was older compared to the Athanasiadis study (M age 75.47 versus M age = 37.7 yrs) and the two studies 
assessed a different number of SNPs (greater in the current study). Although both studies used Caucasian samples 
and analysed the data similarly (additive genetic model, age and sex as covariates), we undertook an additional 
analysis including an extra covariate, hypolipidemic medication usage, which may influence ApoH levels that 
was not considered in the Athanasiadis GWAS. In contrast, we were able to replicate the prior association of the 
missense SNP, Trp335Ser (rs1801690), with the direction of the results consistent to that previously reported24. 
In addition, we also replicated a finding for the rare missense SNP, rs1801689 (Cys325Gly), which has previously 
been linked to ApoH levels in lupus patients22, to venous thrombosis and ApoH levels in a Chinese sample23 and 
to LDL cholesterol levels31. Interestingly, the amino acid changes from these two SNPs alter the binding capacity 
of ApoH for phospholipids32.
We found several of the top APOH SNPs located on chromosome 17 were also nominally associated with 
diabetes type 2 and cognitive performance in older adults in the full Sydney MAS cohort. Replication of these 
results in the smaller OATS cohort found only nominally significant results for the SNP rs2873966 and cognitive 
performance (attention/processing speed) that did not survive multiple testing correction. Moreover, the effects 
in OATS were not in the same direction. However, based on the Sydney MAS results, power calculations suggest 
a sample size of 760 would be required for 80% power. The OATS cohort used for these analyses was considerably 
smaller and hence larger samples are required to replicate these results.
A strength of this study is the use of the same immunoassay for ApoH across studies and that all assays were 
undertaken in the same laboratory, thus minimising phenotypic variability between studies. On the other hand, a 
limitation of this study is the relatively small sample used for discovery and replication. However, given the prior 
genetic association studies using even smaller samples that have found significant relationships between SNPs 
and ApoH levels it is not surprising that we observed significant results in our larger population. Another limita-
tion is that several of the previously identified candidate SNPs were not available in the MAS cohort (due to poor 
imputation quality) and hence their relationships with ApoH levels, cardiovascular and cognitive phenotypes 
were not investigated. We did not observe any other significant SNPs associated with ApoH levels apart from the 
APOH gene locus, suggesting that larger cohorts will be required to find other genes that may influence ApoH, 
which may be of smaller effect.
In conclusion, we found SNPs on chromosome 17, including the APOH gene region, that were associated 
with ApoH levels in two cohorts of older adults that replicated in a sample of middle aged to older adults. We 
also found suggestive evidence for associations between APOH SNPs and (i) diabetes type 2 and (ii) cognitive 
performance. This work lays the foundation to improve our understanding of the genetic regulation of ApoH 
levels and how such variation may contribute to chronic inflammatory disease, diabetes type 2, and age-related 
cognitive performance.
Methods
Samples. Three Australian cohorts of middle-aged to older adults were analysed (n = 1,255). All participants 
provided written informed consent and ethics approval was given by the appropriate committees. The methods 
performed in this project were carried out in accordance with the relevant guidelines and regulations. All studies 
collected a diverse set of data including demographic, neuropsychological, health and medical data and periph-
eral blood samples for protein and DNA analyses. Information on current use of hypolipidemic medication was 
also collected.
Discovery Cohorts (n = 942). Participants were from the Sydney Memory and Ageing Study (Sydney MAS) and 
the Older Australian Twins Study (OATS).
Sydney MAS. Briefly, older adults aged 70–90 years were randomly recruited from the compulsory electoral 
rolls of two Sydney electorates. Exclusion criteria included a diagnosis of dementia, psychotic symptoms or diag-
nosis of schizophrenia/bipolar disease and progressive malignancy. The University of New South Wales and the 
Illawarra Area Health Service Human Research Ethics Committees approved the study. At baseline, there were 
1,037 participants with a mean age of 78.84 years and 44.8% were men. A subsample with both plasma ApoH 
levels and genome-wide genotyping data were used in this study (n = 603). Full details of the study are provided 
elsewhere33.
OATS. Participants aged 65 years and over were recruited through the Australian Twin Registry and a recruit-
ment drive. Exclusion criteria included a current psychosis diagnosis and insufficient English to complete the 
assessment. The Australian Twin Registry, University of New South Wales, University of Melbourne, Queensland 
Institute of Medical Research and the South Eastern Sydney and Illawarra Area Health Service all gave approval 
for the study. Following recruitment, there were 623 participants with a mean age of 70.77 years and 34.8% were 
men. A subsample with both ApoH and genotyping data was used in the current study (n = 339). For further 
details see Sachdev et al.34.
Replication cohort. Over 7,500 people were randomly selected from the compulsory electoral roll of Newcastle, 
Australia, and invited to participate in the Hunter Community Study (HCS). Exclusion criteria included an ina-
bility to speak English and living in a residential care facility. After recruitment, there were 3,207 participants with 
a mean age of 66.3 years and 49.6% were male. Ethics approval for the study was obtained from the Hunter New 
England Local Health District and University of Newcastle Human Research Ethics Committees. A subsample 
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was used in the present study who had available both genome-wide genotyping and plasma ApoH data (n = 313). 
For more details see McEvoy et al.35.
Apolipoprotein H (ApoH) Levels. Plasma ApoH levels were measured in the same laboratory using 
the same measurement method. ApoH levels were assayed using a multiplex bead fluorescence immunoassay 
(WideScreen Human CVD Panel1; Novagen, EMD Chemicals Inc, WI) as per the manufacturer’s instructions. 
Five microliters of plasma was diluted in 1:2,500 using the kit’s dilution buffer. Fluorescence was measured using 
a Bioplex system (Luminex 100, BioRad, Hercules, CA). More details are provided in Song et al.17.
Cardiovascular Phenotypes and Diabetes. Diabetes, myocardial infarction, stroke, hypertension, cho-
lesterol, HDL and LDL cholesterol levels were assessed. Diabetes was defined as self-report of a diagnosis by a 
doctor, current usage of diabetes medication or a fasting blood glucose ≥7.0mM. Participants reported whether 
they ever had been diagnosed by a doctor with the following: (i) a myocardial infarct; and/or (ii) stroke. Current 
hypertension was defined as previous diagnosis and current treatment for hypertension, systolic blood pressure 
≥160 mmHg, or diastolic blood pressure ≥ 95 mmHg. HDL cholesterol levels were estimated in overnight fasting 
peripheral venous blood samples using standard enzymatic colorimetric methods on a COBAS 6000 Analyser 
(Roche, Indianapolis, USA). LDL cholesterol levels were calculated using the Friedewald formula. Current use of 
hypolipidemic medication was assessed from self-reported medication usage.
Cognitive Phenotypes. An extensive battery of cognitive tests was administered to participants of both the 
Sydney MAS and OATS. Details of the specific tests used are given in Sachdev et al.33,34. Cognitive domain scores 
were calculated as an average of the z-scores of the relevant tests: attention/processing speed, memory, verbal 
memory, language, visuo-spatial ability and executive function. Global cognition scores were calculated as the 
average of all domain scores except for verbal memory.
Genotyping. For the majority of participants DNA was extracted using standard procedures from periph-
eral blood samples. For the Sydney MAS and OATS cohorts where blood samples were not available, DNA was 
extracted from saliva samples or cell lines (< 5%).
Sydney MAS. Genome-wide genotyping was undertaken using the Affymetrix Genome-wide Human SNP 
Array 6.0 (California, USA) at the Ramaciotti Centre, UNSW Australia. Of the 972 DNA samples available, six 
samples were not successfully genotyped (insufficient DNA/failed genotyping). Genotypes were called using the 
CRLMM package (v1.10.0) in R (v2.12.1) and release 31 SNP6 annotations were used. Genotyped SNPs were 
excluded if the call rate was < 95%, if the p-value for Hardy-Weinberg equilibrium was < 10−6, and/or if the 
minor allele frequency was < 0.01%. One participant was excluded due to a poor genotyping call rate (< 95%). 
Relatedness checks were undertaken using identity-by-descent analysis in PLINK36, three pairs of siblings were 
identified and only one of each pair was kept in the dataset. Sex checks were performed using PLINK, which con-
firmed recorded gender. Assessment of population stratification and identification of ethnic outliers was under-
taken using EIGENSTRAT (Price et al., 2006). Ethnic outliers were excluded (n = 37) and 17 significant principal 
components were observed. After quality control checks, there were 925 Sydney MAS participants (45.1% male) 
with data for 734,550 SNPs and an average genotyping call rate of 99.5%. Imputation was undertaken using the 
HapMap2 reference data (release 22, build 36) and MaCH37,38. Poorly imputed SNPs (R2 ≤ 0.6) were excluded 
from further analyses.
OATS. Samples (n = 548) were genotyped at the University of Queensland Diamantina Institute, Australia, 
using the Illumina Omni Express array (California, USA) following the manufacturer’s instructions. Genotypes 
(n = 733,202) were called using Illumina Genome Studio V2011.1. Quality control procedures were the same 
as for Sydney MAS. No participants were excluded due to poor genotyping call rates. Using PLINK, relatedness 
(identity-by-descent) and sex checks were undertaken to confirm family relationships and sex. Six samples were 
excluded due to unexpected relatedness or incorrect sex. Using EIGENSTRAT 25 ethnic outliers were identified, 
which were omitted from further analysis and three significant principal components were observed. After qual-
ity control checks, there was genotyping data available on 646,791 SNPs for 517 participants (35.2% male) with a 
mean genotyping call rate of 99.9%. Imputation was undertaken using the HapMap2 reference data as described 
for Sydney MAS.
HCS. Genome-wide genotyping was undertaken using the Affymetrix Axiom Kaiser array following the recom-
mended protocol. Quality control filters used were similar to Sydney MAS. SNPs were excluded if the genotyping 
call rate was < 95%, the Hardy-Weinberg equilibrium p-value was < 1 × 10−6, or the MAF < 0.01%. Participants 
were excluded if the genotyping call rate was low (< 95%) and if the sex checks were discordant with the recorded 
gender. Relatedness checks were undertaken and if first or second-degree relatives were identified, only one 
family member was retained in the analysis. After EIGENSTRAT analysis ethnic outliers were identified and 
omitted from further analysis, 17 significant principal components were observed. After completion of quality 
control checks, there were 2,088 participants (49.6% male) with data for 739,276 SNPs and a mean genotyping call 
rate of 99.1%. Imputation was undertaken using the HapMap2 reference data (release 22, build 36) and MaCH 
v1.0.1637,38.
Statistical Analyses. Genome-wide Association Study (GWAS). ApoH was square root transformed to 
improve normality. Using an additive genetic model and multiple linear regression, a GWAS was undertaken 
adjusting for age, sex and ApoH assay batch number (model 1). Model 2 was also adjusted for the use of hypolipi-
demic medication, a possible confounder. In MAS and OATS, the GWAS was undertaken using mach2qtl37,38 
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and merlin39, respectively. An inverse-variance weighted meta-analysis of the GWAS results was undertaken in 
Sydney MAS and OATS using METAL40. Principal components were not used to account for population strat-
ification in the analysis as we had removed any ethnic outliers in both MAS and OATS and the meta-analysis 
genomic inflation factor was acceptable (0.995). Linkage disequilibrium between SNPs (r2) was calculated using 
PLINK.
Replication of genome-wide significant (p < 5 × 10−8) and suggestive results (p < 1 × 10−5) was performed 
in the HCS (n = 313) using linear regression, an additive genetic model and GenABEL41. Models 1 and 2 were 
adjusted for population substructure using the first 4 principal components.
Conditional and Joint Analysis. Conditional and joint analysis (COJO) as implemented in the program GCTA42 
was used to select a subset of associated SNPs with p-values < threshold (p0 = 5 × 10−8). This method uses a ref-
erence panel of SNPs to estimate the LD between the SNPs and the meta-analysis summary statistics. The method 
starts with the top SNP (least p < p0) in the meta-analysis and then the p-values for all the remaining SNPs are 
calculated conditional on the selected SNP (top SNP). It then selects the next top SNP in the conditional analysis 
(p < p0) and proceeds to fit all the selected SNPs in the model dropping all those SNPs with p-values > p0. The 
iteration continues until no SNP is added or dropped from the model thus finding a subset of associated SNPs 
with a threshold for LD (r2 < 0.9) between SNPs. Finally, a joint analysis of the subset of associated SNPs is per-
formed. For the COJO analysis we used the results from the ApoH meta-analysis (discovery results) and the MAS 
imputed data as the reference panel.
Replication of prior genetic results. Replication of prior results (N = 15 SNPs) from candidate gene studies and 
the previous GWAS was undertaken using an additive genetics model and linear regression. P-values < 0.003 
were considered significant after Bonferroni correction for the number of statistical tests undertaken 
(p = 0.05/15 = 0.003).
Analysis of Top APOH SNPs with cardiovascular-related and cognitive phenotypes. Analyses 
were undertaken in Sydney MAS using an additive model and linear (continuous variables) or logistic regression 
(categorical variables). Cardiovascular phenotypes and diabetes analyses examining the top 25 GWAS identified 
SNPs were undertaken using age and sex as covariates. For cognitive phenotypes, the additional covariates used 
were years of education and non-English speaking background. Replication of the top results (< 0.05) was under-
taken in the OATS cohort.
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